Elevance Health Inc. closed 27.50% below its 52-week high of $567.26, which the company achieved on September 3rd.

Elevance Health Inc. closed $174.10 below its 52-week high ($567.26), which the company achieved on September 3rd.

Health-care companies rose sharply amid strong earnings. Elevance Health, the health insurer formerly known as Anthem, posted fourth-quarter profit and revenue ahead of Wall Street targets ...

Analyst David Windley from Jefferies maintained a Buy rating on Elevance Health (ELV – Research Report) and increased the price target to

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target

Elevance Health's board has raised the health insurer and healthcare-services provider's quarterly dividend by 4.9%, to $1.71 from $1.63. The new payout, equal to $6.84 a year, represents an ...

Elevance Health (NYSE:ELV – Free Report) had its price target upped by Barclays from $501.00 to $512.00 in a report published on Friday,Benzinga reports. The firm currently has an overweight rating on the stock.

The SPDR Health Care Sector exchange-traded fund, which tracks the health-care industry group of the broad S&P 500, rose by roughly 2%, and is now up about 7% for the year to date.

We read every day so you don't have to. Sign up for CNN Business' nightly newsletter for the top stories you need to know.

The Public Health Agency of Canada is part of the federal health portfolio. Our activities focus on protecting against threats to public health, preventing and reducing diseases and injury, and promoting health, well-being and equity.

The SPDR Health Care Sector exchange-traded fund, which tracks the health-care industry group of the broad S&P 500, rose by roughly 2%, and is now up about 7% for the year to date.

TD Cowen analyst Ryan Langston has maintained their bullish stance on ELV stock, giving a Buy rating on January 24.Invest with Confidence: